Franklin Resources Inc. Sells 1,060 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Franklin Resources Inc. trimmed its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 3.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,405 shares of the company’s stock after selling 1,060 shares during the period. Franklin Resources Inc.’s holdings in Amphastar Pharmaceuticals were worth $1,018,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Smartleaf Asset Management LLC boosted its holdings in Amphastar Pharmaceuticals by 222.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock valued at $26,000 after acquiring an additional 493 shares during the period. Parkside Financial Bank & Trust increased its stake in Amphastar Pharmaceuticals by 806.5% in the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company’s stock worth $36,000 after purchasing an additional 871 shares during the period. TD Private Client Wealth LLC lifted its position in Amphastar Pharmaceuticals by 22.7% in the fourth quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company’s stock valued at $78,000 after purchasing an additional 388 shares during the last quarter. KBC Group NV boosted its stake in shares of Amphastar Pharmaceuticals by 43.1% during the fourth quarter. KBC Group NV now owns 2,159 shares of the company’s stock valued at $80,000 after purchasing an additional 650 shares during the period. Finally, PNC Financial Services Group Inc. grew its holdings in shares of Amphastar Pharmaceuticals by 90.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,203 shares of the company’s stock worth $156,000 after purchasing an additional 1,992 shares during the last quarter. 65.09% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on AMPH shares. Piper Sandler lowered their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research note on Friday, March 21st. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th.

Amphastar Pharmaceuticals Stock Down 3.8 %

Shares of Amphastar Pharmaceuticals stock opened at $23.50 on Wednesday. The company has a 50-day simple moving average of $28.33 and a two-hundred day simple moving average of $37.80. Amphastar Pharmaceuticals, Inc. has a 52-week low of $22.74 and a 52-week high of $53.96. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The stock has a market capitalization of $1.12 billion, a PE ratio of 7.83, a price-to-earnings-growth ratio of 2.19 and a beta of 0.79.

Insider Buying and Selling

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total transaction of $116,521.74. Following the sale, the chief financial officer now directly owns 97,363 shares in the company, valued at approximately $2,681,377.02. This trade represents a 4.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 27.10% of the stock is owned by company insiders.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.